TECENTRIQ HYBREZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECENTRIQ HYBREZA (TECENTRIQ HYBREZA).
Programmed death-ligand 1 (PD-L1) blocking antibody that binds to PD-L1, preventing interaction with PD-1 and B7.1, thereby reactivating antitumor immune responses.
| Metabolism | Metabolism is not a major clearance pathway; cleared primarily via catabolism. |
| Excretion | Almost entirely renal as unchanged drug (approximately 90% of a subcutaneously administered dose is eliminated via the kidneys within 96 hours). Biliary/fecal elimination accounts for less than 1%. |
| Half-life | Terminal elimination half-life is approximately 6.5 days (range 4–9 days), supporting a subcutaneous dosing interval of every 3 weeks. |
| Protein binding | Approximately 70% bound to plasma proteins, primarily albumin and IgG. |
| Volume of Distribution | Volume of distribution at steady state (Vss) is approximately 0.12 L/kg, indicating limited extravascular distribution consistent with a monoclonal antibody. |
| Bioavailability | Subcutaneous bioavailability is approximately 80% compared to intravenous administration. |
| Onset of Action | Subcutaneous administration: Clinical effect observed within 3–4 weeks following initiation of therapy. |
| Duration of Action | Duration of PD-1 blockade persists for approximately 2–3 half-lives (13–20 days) beyond discontinuation; clinical response may last for months after treatment cessation. |
840 mg intravenously every 2 weeks, or 1200 mg intravenously every 3 weeks, or 1680 mg intravenously every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (eGFR <30 mL/min) has not been studied; use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment is recommended for elderly patients (>65 years), but close monitoring for adverse reactions is advised due to potential age-related comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECENTRIQ HYBREZA (TECENTRIQ HYBREZA).
| Breastfeeding | It is unknown whether TECENTRIQ HYBREZA is excreted in human milk. However, because many antibodies are excreted in human milk and there is potential for absorption leading to adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for at least 5 months after the last dose. M/P ratio is not available. |
| Teratogenic Risk | Based on its mechanism of action as a PD-L1 inhibitor, there is potential for fetal harm. In animal reproduction studies, inhibition of the PD-1/PD-L1 pathway has been associated with increased risk of immune-mediated rejection of the developing fetus, leading to fetal loss. Human data are limited, but it is presumed that TECENTRIQ HYBREZA may cause fetal harm when administered to a pregnant woman. The risk is present throughout pregnancy, with particular concern during the second and third trimesters due to the potential for immune-mediated effects on fetal development. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
None.
| Precautions | ["Immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, dermatologic reactions)","Infusion-related reactions","Embryo-fetal toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor for immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies (e.g., hypophysitis, thyroid disorders, type 1 diabetes mellitus), nephritis, and dermatologic reactions. In pregnant patients, monitor for signs of fetal distress and growth abnormalities. Assess liver function tests, thyroid function, and renal function at baseline and periodically during treatment. |
| Fertility Effects | No specific human studies on fertility have been conducted. In animal studies, inhibition of PD-1/PD-L1 signaling did not directly impair fertility, but the potential for immune-mediated effects on reproductive tissues cannot be excluded. Based on mechanism, there may be a potential risk to reproductive function. |